Given the increased prevalence of insulin resistance, type 2 diabetes and other metabolic diseases in post-menopausal women [36,39], a better understanding of the regulatory loops that could take place between GRK2 and estrogen-mediated pathways in metabolically relevant organs and specific cell types could serve as a proof of concept for novel therapies that are based on GRK2 inhibition, particularly tailored for female patients. Here, GRK2 is linked to metabolic disease.